Kidney Effects in the MOXIe Trial: Presentation at ERA-EDTA 2020

Friedreich’s Ataxia (FA) is a rare, progressive, and debilitating genetic disorder with no approved treatments. Kidney function was assessed in patients with Friedreich’s ataxia in Part 2 of MOXIe, a Phase 2 international, multicenter, double-blind, randomized, placebo-controlled study of omaveloxolone in FA.